




## STATE MEDICAID P&T COMMITTEE MEETING

Thursday, May 15, 2014

7:00 a.m. to 8:30 a.m.

Cannon Health Building

Room 114



# MINUTES

### Committee Members Present:

Kort Delost, R.Ph.

Lisa Hunt, R.Ph.

Roger Martenau, M.D.

Ellie Brownstein, M.D.

Jameson Rice, Pharm.D.

Beth Johnson, R.Ph.

Julia Ozbolt, M.D.

### Committee Members Excused:

Elizabeth Young, Pharm.D.

### Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, Pharm.D.

Trevor Smith, CPhT

Richard Sorenson, RN

### University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Bryan Larson, Pharm.D.

### Other Individuals Present:

Joanita Lake, UofU

Camille Kerr, Allergan

Lori Howarth, Bayer

Edie Dodson, Genzyme

Gary Oderda, UofU

Paul Bonham, NovoNordisk

Meeting conducted by: Kort Delost

---

1. **Review and Approval of March Minutes:** Minutes for March and April were reviewed. Roger Martenau made a motion to approve the March minutes, Beth Johnson seconded the motion. All in favor. Kort Delost pointed out a typing error in the April minutes. He said that other than that they are correct. Roger Martenau made a motion to approve the April minutes pending the correction. Beth Johnson seconded. All in favor.
2. **Housekeeping:** Lisa Hunt reminded people in attendance today to sign in. Lisa also reported that she has begun to review bids for 2015 preferred drug list. She said that there will be no P&T meeting held during June.
3. **Drug Utilization Review (DUR) Board update:** Robyn Seely reported that the May DUR Board discussed Juxtapid and Kynamro, and next month the DUR board will re-review Hepatitis C drugs.

4. **Antihistamines First Generation Products:** Melissa Archer presented a review of the first generation antihistamine agents. She presented peer-reviewed research regarding the safety and efficacy of each agent, disease-state treatment guidelines and Utah Medicaid utilization data was presented.

5. **No Public Comment**

6. **Committee discussion**

- a. Lisa Hunt presented the other states report, included PDLs in the drug class for other states.
- b. Ellie Brownstein said that many of the combination agents contain acetaminophen, and are a concern for safety.
- c. Juila Ozbolt said that hydroxyzine and cyproheptadine is used for other things including sleep, appetite stimulants, and migraine treatments.
- d. Lisa Hunt shared information from the OTC covered list, and the policy on these drugs from the pharmacy manual.
- e. Kort Delost said that because of the other prescribed uses of hydroxyzine, than for antihistamine purposes, it should be included as a preferred agent.
- f. Ellie Brownstein said that she feels the same about the diphenhydramine products.
- g. Beth Johnson said that most people who take the first generation products use them for reasons other than for treating allergies. The non-sedating second generation products are used to treat allergies now.
- h. Ellie Brownstein said that she doesn't think that the combination products are equally safe and effective, particularly the products that contain acetaminophen.
- i. Kort Delost mentioned that there are two different products that contain hydroxyzine, and they differ in the salt that the medication is made up of.
- j. Beth Johnson said that she think that any Hydroxyzine product should be included.
- k. Ellie Brownstein made a motion that the first generation antihistamines are equally safe and effective. Julia Ozbolt seconded the motion. All in favor.
- l. Ellie Brownstein made another motion saying that diphenhydramine, both salts of hydroxyzine, and cyproheptadine should be included as preferred agents on the PDL. Beth Johnson seconded the motion. All in favor.
- m. Ellie Brownstein made another motion that combinations can be included in the PDL, but to make a note about potential safety issues in acetaminophen containing products on the PDL, and that because of this they are not recommended to be used. Beth Johnson seconds the motion, all in favor.
- n. Beth Johnson said that the new product Diclegis (doxylamine/pyroxidine) should be included in a different part of the PDL.
- o. Lisa Hunt pointed out that both agents in Diclegis are not available individually from Utah Medicaid.
- p. Beth Johnson made a motion to include the Diglegis product in either the combination or the individual products for inclusion in the PDL. Lisa Hunt seconded the motion. All in favor.

7. **Antihistamines Second Generation Products:** Bryan Larson presented a review of the second generation antihistamine agents. Peer-reviewed research regarding the safety and efficacy of each agent, disease-state treatment guidelines and Utah Medicaid utilization data was presented.
8. **No Public Comment**
9. **Committee discussion**
  - a. Lisa Hunt reported on the other States status on these drugs. She also shared the criteria on some of these drugs for Utah Medicaid. Some require a PA, and some will work with an automatic PA, to look for past usage of a drug (step through)
  - b. Ellie Brownstein made a motion that the second generation antihistamine agents are equally safe and effective. Beth Johnson seconded the motion. All in favor.
  - c. Jameson Rice said that some products, such as fexofenadine can be better for some patients.
  - d. Ellie Brownstein said that for patients who need a specific product, they can fail on one, and receive another one that may be non-preferred. The products will still be available.
  - e. Julia Ozbolt asked about liquid and tablet formulations, and if they should both be available.
  - f. Julia Ozbolt made a motion to include pill and liquid formulations in the same products. She added that based on high utilization, to include cetirizine and loratadine products as preferred agents. Ellie Brownstein seconded the motion. All in favor.
10. **Meeting Adjourned** – Beth Johnson made a motion to adjourn the meeting, Ellie Brownstein seconded, all in motion.
11. Next meeting is scheduled for July 17, 2014. Vitamin D analogues and bile sequestration agents will be discussed.

---

Minutes prepared by Trevor Smith

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)